Liu Y, Su Z, Tavana O, Gu W
Cancer Cell. 2024; 42(6):946-967.
PMID: 38729160
PMC: 11190820.
DOI: 10.1016/j.ccell.2024.04.009.
Skhoun H, Khattab M, Belkhayat A, Chebihi Z, Bakri Y, Dakka N
Mol Biol Rep. 2022; 49(9):8291-8300.
PMID: 35705773
DOI: 10.1007/s11033-022-07643-3.
Li H, Zhang W, Zhao K, Zhao D, Zheng S, Hu Y
J Biol Chem. 2020; 295(12):4049-4063.
PMID: 32005663
PMC: 7086043.
DOI: 10.1074/jbc.RA119.011411.
Mohammed Basabaeen A, Abdelgader E, Ahmed Babekir E, Abdelrahim S, Eltayeb N, Altayeb O
Asian Pac J Cancer Prev. 2019; 20(5):1579-1585.
PMID: 31128065
PMC: 6857868.
DOI: 10.31557/APJCP.2019.20.5.1579.
Huang C, Wu S, Ji H, Yan X, Xie Y, Murai S
Sci Adv. 2017; 3(10):e1701383.
PMID: 29057323
PMC: 5647124.
DOI: 10.1126/sciadv.1701383.
Transcription factor Yin Yang 2 is a novel regulator of the p53/p21 axis.
Kasim V, Xie Y, Wang H, Huang C, Yan X, Nian W
Oncotarget. 2017; 8(33):54694-54707.
PMID: 28903375
PMC: 5589614.
DOI: 10.18632/oncotarget.18005.
ALDH1L1 variant rs2276724 and mRNA expression predict post-operative clinical outcomes and are associated with TP53 expression in HBV-related hepatocellular carcinoma.
Zhu G, Liao X, Han C, Liu X, Yu L, Qin W
Oncol Rep. 2017; 38(3):1451-1463.
PMID: 28714006
PMC: 5549030.
DOI: 10.3892/or.2017.5822.
Molecularly targeted therapies for p53-mutant cancers.
Zhao D, Tahaney W, Mazumdar A, Savage M, Brown P
Cell Mol Life Sci. 2017; 74(22):4171-4187.
PMID: 28643165
PMC: 5664959.
DOI: 10.1007/s00018-017-2575-0.
Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death.
Cheteh E, Augsten M, Rundqvist H, Bianchi J, Sarne V, Egevad L
Cell Death Dis. 2017; 8(6):e2848.
PMID: 28569790
PMC: 5520886.
DOI: 10.1038/cddis.2017.225.
PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK.
Lu T, Zou Y, Xu G, Potter J, Taylor G, Duan Q
Oncotarget. 2016; 7(50):83017-83030.
PMID: 27806324
PMC: 5347749.
DOI: 10.18632/oncotarget.12940.
Cancer-specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis.
Candeias M, Hagiwara M, Matsuda M
EMBO Rep. 2016; 17(11):1542-1551.
PMID: 27702985
PMC: 5090711.
DOI: 10.15252/embr.201541956.
Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi.
Liao X, Han C, Qin W, Liu X, Yu L, Lu S
Am J Transl Res. 2016; 8(4):1799-812.
PMID: 27186304
PMC: 4859909.
Emerging role of transcription factor-microRNA-target gene feed-forward loops in cancer.
Wu Q, Qin H, Zhao Q, He X
Biomed Rep. 2015; 3(5):611-616.
PMID: 26405533
PMC: 4535151.
DOI: 10.3892/br.2015.477.
The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis.
Ruan X, Li S, Meng X, Geng P, Gao Q, Ao X
Medicine (Baltimore). 2015; 94(38):e1588.
PMID: 26402821
PMC: 4635761.
DOI: 10.1097/MD.0000000000001588.
Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo.
He X, Liu F, Yan J, Zhang Y, Yan J, Shang H
Sci Rep. 2015; 5:8705.
PMID: 25732051
PMC: 4346796.
DOI: 10.1038/srep08705.
Functional repair of p53 mutation in colorectal cancer cells using trans-splicing.
He X, Liao J, Liu F, Yan J, Yan J, Shang H
Oncotarget. 2015; 6(4):2034-45.
PMID: 25576916
PMC: 4385834.
DOI: 10.18632/oncotarget.2988.
Human induced pluripotent stem cell derived erythroblasts can undergo definitive erythropoiesis and co-express gamma and beta globins.
Yang C, French A, Goh P, Pagnamenta A, Mettananda S, Taylor J
Br J Haematol. 2014; 166(3):435-48.
PMID: 24837254
PMC: 4375519.
DOI: 10.1111/bjh.12910.
Development of an ELISA detecting Tumor Protein 53-Induced Nuclear Protein 1 in serum of prostate cancer patients.
Saadi H, Seillier M, Jose Sandi M, Peuget S, Kellenberger C, Gravis G
Results Immunol. 2014; 3:51-6.
PMID: 24600558
PMC: 3908328.
DOI: 10.1016/j.rinim.2013.05.002.
Loss of Grainy head-like 1 is associated with disruption of the epidermal barrier and squamous cell carcinoma of the skin.
Mlacki M, Darido C, Jane S, Wilanowski T
PLoS One. 2014; 9(2):e89247.
PMID: 24586629
PMC: 3930704.
DOI: 10.1371/journal.pone.0089247.
Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva J, Rangel L, Costa D, Cordeiro Y, de Moura Gallo C
Biosci Rep. 2013; 33(4).
PMID: 24003888
PMC: 3728989.
DOI: 10.1042/BSR20130065.